Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Apple Restores Telegram to App Store After Content Policy Violation 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
NAPANEE, Ontario, March 16, 2018 -- ABcann Global Corporation (TSXV:ABCN) (Frankfurt:23Q) (OTC:ABCCF) ("ABcann" or the "Company") announced that Ken Clement, ABcann's founder and director, has resigned from the Board of Directors.
Paul Lucas, ABcann's Chair, commented, "On behalf of the Board, we thank Ken for his vision in starting the company and growing it from a start-up organization into a well-funded publicly-traded licensed producer with a bright future. We wish Ken well in his future endeavours."
About ABcann:
ABcann holds production and sales licenses from Health Canada. Its flagship facility in Napanee, Ontario contains proprietary plant-growing technology, centred on its specially designed, environmentally-controlled growing chambers. This approach results in the production of pharmaceutical-grade cannabis products.
The Company is expanding its cultivation capacity and pursuing partnerships and product development opportunities domestically, as well as in select international markets, such as Germany, Australia and Israel.
ON BEHALF OF THE BOARD OF DIRECTORS
"Barry Fishman"
Barry Fishman
CEO and Director
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact: Barry Fishman (CEO and Director) [email protected] Michael Bumby (CFO) [email protected]
